

Contents

Preface to the First Edition	viii
Preface to the Second Edition	ix
Introduction	xi
Acknowledgements for the First Edition	xiii
Acknowledgements for the Second Edition	xiv
Contributors	xvi

Case detection

1. What is the role of case detection in tuberculosis control? ¹ <i>F. Luelmo</i>	3
2. What is a case of tuberculosis? ¹ <i>F. Luelmo</i>	5
3. What is the role of sputum microscopy in patients attending health facilities? <i>F. Luelmo</i>	7
4. How many bacilli are present in a sputum specimen found positive by smear microscopy? <i>K. Toman</i>	11
5. How reliable is smear microscopy? <i>K. Toman</i>	14
6. What are the main causes of false-positive and false-negative sputum smears? <i>K. Toman</i>	23
7. What are the main consequences of false-positive and false-negative sputum smears? <i>T. Frieden</i>	28
8. What are the advantages and disadvantages of fluorescence microscopy? <i>K. Toman</i>	31
9. What is the role of mycobacterial culture in diagnosis and case definition? ¹ <i>A. Van Deun</i>	35
10. What is the probability of obtaining a negative culture from a sputum specimen found positive by smear microscopy? <i>K. Toman</i>	44

¹ Based on the chapter in the previous edition by K. Toman.

- | | |
|---|----|
| 11. What is the additional yield from repeated sputum examinations by smear microscopy and culture? ¹ <i>A. Harries</i> | 46 |
| 12. How reliable is chest radiography? ¹ <i>R. Koppaka & N. Bock</i> | 51 |
| 13. What are the relative merits of chest radiography and sputum examination (smear microscopy and culture) in case detection among new outpatients with prolonged chest symptoms? ¹ <i>A. Harries</i> | 61 |
| 14. How does pulmonary tuberculosis develop and how can it be detected at an early stage? <i>K. Toman</i> | 66 |
| 15. What is the role of case detection by periodic mass radiographic examination in tuberculosis control? ¹ <i>H. Rieder</i> | 72 |
| 16. How does the diagnosis of tuberculosis in persons infected with HIV differ from diagnosis in persons not infected with HIV? <i>A. Harries</i> | 80 |
| 17. What is the role of tuberculin skin testing in the diagnosis of tuberculosis? <i>D. Menzies</i> | 84 |
| 18. What is the current and potential role of diagnostic tests other than sputum microscopy and culture? <i>D. Menzies</i> | 87 |
| 19. How can public and private sectors cooperate to detect, treat, and monitor tuberculosis cases? <i>T. Frieden</i> | 92 |

Treatment

- | | |
|--|-----|
| 20. What were the main landmarks in the development of tuberculosis treatment? <i>K. Toman</i> | 99 |
| 21. How does tuberculosis treatment work? <i>K. Toman</i> | 102 |
| 22. What is the role of host factors in the pathogenesis, prevention, and treatment of tuberculosis? <i>M. Iademarco & M. Reichler</i> | 106 |
| 23. What is the therapeutic effect and what is the toxicity of antituberculosis drugs? ¹ <i>T. Frieden & M. Espinal</i> | 110 |
| 24. What is the purpose of the initial intensive phase of two-phase treatment? <i>K. Toman</i> | 122 |
| 25. What are the current recommendations for standard regimens? <i>A. Harries</i> | 124 |
| 26. What are the diagnostic categories and what is the rationale for these categories? <i>A. Harries</i> | 128 |
| 27. What is intermittent treatment and what is the scientific basis for intermittency? ¹ <i>T. Frieden</i> | 130 |

¹ Based on the chapter in the previous edition by K. Toman.

CONTENTS

28. What is the dosage of drugs in daily and intermittent regimens? <i>H. Rieder</i>	139
29. What is the evidence for tuberculosis drug dosage recommendations? <i>H. Rieder</i>	141
30. What is the optimum duration of treatment? ¹ <i>T. Santha</i>	144
31. What are the most common adverse drug events to first-line tuberculosis drugs, and what is the procedure for reintroduction of drugs? <i>A. Harries</i>	152
32. What are the merits of thioacetazone as a companion drug to isoniazid, and what is the efficacy of the regimen of isoniazid plus thioacetazone? ¹ <i>H. Rieder</i>	159
33. How does management of extrapulmonary tuberculosis differ from that of pulmonary tuberculosis? <i>R. Balasubramanian, R. Rajeswari & T. Santha</i>	162
34. How does treatment of tuberculosis differ in patients with pregnancy, liver disease, or renal disease? <i>A. Harries</i>	166
35. How does treatment of tuberculosis differ in persons infected with HIV? <i>A. Harries</i>	169
36. What were the main findings of the Madras study comparing home and sanatorium treatment? <i>K. Toman</i>	173
37. How frequently do patients stop taking treatment prematurely? <i>J. Sbarbaro</i>	181
38. What are the advantages of direct observation of treatment? ¹ <i>J. Sbarbaro</i>	183
39. Why does treatment fail and what can be done to avoid poor treatment outcome? ¹ <i>F. Luclmo</i>	185
40. What are the advantages and disadvantages of fixed-dose combinations of antituberculosis drugs? <i>K. Laserson & M. Iademarco</i>	189
41. How does drug resistance develop? <i>K. Toman</i>	193
42. Why are special precautions needed to protect rifampicin? <i>A. Vernon</i>	195
43. What are the different types of drug resistance? ¹ <i>M. Espinal</i>	198
44. What is the "fall and rise" phenomenon and the "sequential regimen" mechanism? ¹ <i>M. Espinal</i>	200
45. How many drug-resistant tubercle bacilli can be found in the sputum of patients who have never received treatment for tuberculosis? ¹ <i>A. Pablos-Mendez</i>	203

¹ Based on the chapter in the previous edition by K. Toman.

46. What are the causes of drug-resistant tuberculosis?
M. Espinal & T. Frieden 207
47. How can the emergence of drug resistance be prevented? *T. Frieden* 209
48. How reliable are drug susceptibility tests?¹ *M. Espinal* 211
49. What are the possible consequences of inaccurate drug-susceptibility testing?¹ *M. Espinal* 213
50. What reserve regimens are available and what is their place in tuberculosis control programmes?¹ *M. Espinal* 215
51. What is the role of treatment of latent tuberculosis infection in a tuberculosis control programme? *M.E. Villarino* 220
52. What is the epidemiological impact of treatment of latent tuberculosis infection? *Z. Taylor* 226

Monitoring

53. What is the health, social, and economic burden of tuberculosis?
I. Smith 233
54. What are the global targets for tuberculosis control, and what is the basis of these targets? *I. Smith* 238
55. What is DOTS? *I. Smith* 241
56. Is DOTS cost-effective? *I. Smith* 246
57. How can the progress of treatment be monitored?¹ *T. Santha* 250
58. How effective is tuberculosis treatment and what are the needs for the future?¹ *T. Santha* 253
59. Is primary drug resistance a menace to the control of tuberculosis?¹
M. Espinal & T. Frieden 256
60. What are the keys to cure? *K. Toman* 260
61. What is the significance of default (treatment interruption) in the treatment of tuberculosis?¹ *N Bock* 263
62. How important is follow-up and what is the frequency of relapse after the completion of treatment?¹ *T. Santha* 267
63. Why is a recording and reporting system needed, and what system is recommended? *D. Maher & M. Raviglione* 270
64. When should tuberculosis patients be hospitalized, and how infectious are tuberculosis patients while on treatment?² *E.A. Talbot & C.D. Wells* 274

¹ Based on the chapter in the previous edition by K. Toman.

² Based on the chapter in the previous edition by K. Toman.

CONTENTS

65. What is nosocomial transmission of tuberculosis and how can it be prevented? <i>P.M. Simone</i>	278
66. Where is tuberculosis usually spread and how can spread be reduced? <i>H. Rieder</i>	282
67. What are the principles and requirements of a controlled clinical trial? <i>F. Rehman</i>	285
68. What is molecular epidemiology and what is its role in tuberculosis control? <i>K. DeRiemer & P.M. Small</i>	296
69. Can tuberculosis be controlled? <i>T. Frieden</i>	301
70. Can effective case detection and treatment prevent and reverse drug resistance in a community? <i>M. Raviglione</i>	310
71. What are the indicators of an effective tuberculosis control programme? <i>F. Luelmo & T. Frieden</i>	315
72. What are examples of effective tuberculosis control programmes? <i>M. Raviglione & T. Frieden</i>	318
73. What are the relative priorities for a tuberculosis control programme, and what activities should not be undertaken? <i>F. Luelmo & T. Frieden</i>	322
74. What is the impact of HIV on the epidemiology of tuberculosis in a community? <i>A. Harries</i>	326
75. How can tuberculosis control services be promoted and sustained? <i>T. Frieden</i>	330